CN1910183A - 四氢咔啉化合物作为抗癌药 - Google Patents

四氢咔啉化合物作为抗癌药 Download PDF

Info

Publication number
CN1910183A
CN1910183A CNA2005800030203A CN200580003020A CN1910183A CN 1910183 A CN1910183 A CN 1910183A CN A2005800030203 A CNA2005800030203 A CN A2005800030203A CN 200580003020 A CN200580003020 A CN 200580003020A CN 1910183 A CN1910183 A CN 1910183A
Authority
CN
China
Prior art keywords
substituted
compound
hydrogen
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800030203A
Other languages
English (en)
Chinese (zh)
Inventor
王为波
Z·-J·倪
P·巴杉蒂
S·佩奇
夏奕
N·布拉默尔
M·特罗托
E·加赞
K·威曼
D·蒂伯
程捷恺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1910183A publication Critical patent/CN1910183A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2005800030203A 2004-01-23 2005-01-24 四氢咔啉化合物作为抗癌药 Pending CN1910183A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53898004P 2004-01-23 2004-01-23
US60/538,980 2004-01-23

Publications (1)

Publication Number Publication Date
CN1910183A true CN1910183A (zh) 2007-02-07

Family

ID=34807249

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800030203A Pending CN1910183A (zh) 2004-01-23 2005-01-24 四氢咔啉化合物作为抗癌药

Country Status (9)

Country Link
US (1) US7855295B2 (https=)
EP (1) EP1706404A2 (https=)
JP (1) JP2007518822A (https=)
CN (1) CN1910183A (https=)
AU (1) AU2005206570A1 (https=)
BR (1) BRPI0506977A (https=)
CA (1) CA2554150A1 (https=)
MX (1) MXPA06008211A (https=)
WO (1) WO2005070930A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591348B (zh) * 2008-05-30 2011-07-27 首都医科大学 四氢咔啉酰氨基酸苄酯及其制备方法和应用
CN101597289B (zh) * 2008-06-02 2011-09-21 首都医科大学 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用
CN103087062A (zh) * 2013-01-19 2013-05-08 安徽师范大学 N-磺酰基取代-β-四氢咔啉衍生物的制备方法
CN106967063A (zh) * 2017-03-21 2017-07-21 浙江大学 1‑三氟甲基‑1,2,3,4‑四氢‑β‑咔啉衍生物及其制备方法
CN110791389A (zh) * 2019-09-30 2020-02-14 义乌欧风汽车用品有限公司 一种环保型除胶剂及其制备方法和应用
CN113527289A (zh) * 2015-09-23 2021-10-22 米纳瓦生物技术公司 筛选分化干细胞的试剂的方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2214485B1 (en) * 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
EP2050747A1 (en) * 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
CA2763479A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Processes for the preparation of substituted tetrahydro beta-carbolines
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
ES2693247T3 (es) * 2010-07-06 2018-12-10 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012127885A1 (ja) 2011-03-18 2012-09-27 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
EP3366685A1 (en) * 2012-01-09 2018-08-29 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
JP6592197B2 (ja) * 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
US20250186437A1 (en) * 2021-12-31 2025-06-12 Ptc Therapeutics, Inc. Carboline compounds and use thereof
CN120265629A (zh) * 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855147D1 (de) 1987-07-20 1996-05-02 Duphar Int Res 8,9-Anellierte 1,2,3,4-Tetrahydro-beta-carbolin-Derivate
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
JPH03287586A (ja) 1990-04-02 1991-12-18 Taisho Pharmaceut Co Ltd テトラヒドロ―β―カルボリン誘導体
JP3287586B2 (ja) 1991-07-09 2002-06-04 キヤノン株式会社 カラー画像処理方法、及びカラー画像処理装置
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
US5622960A (en) * 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
JP2000508302A (ja) * 1996-04-04 2000-07-04 エフ．ホフマン―ラ ロッシュ エイジー 抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用
FR2796644B1 (fr) 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6720331B2 (en) * 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
JP2005508968A (ja) * 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591348B (zh) * 2008-05-30 2011-07-27 首都医科大学 四氢咔啉酰氨基酸苄酯及其制备方法和应用
CN101597289B (zh) * 2008-06-02 2011-09-21 首都医科大学 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用
CN103087062A (zh) * 2013-01-19 2013-05-08 安徽师范大学 N-磺酰基取代-β-四氢咔啉衍生物的制备方法
CN103087062B (zh) * 2013-01-19 2015-06-03 安徽师范大学 N-磺酰基取代-β-四氢咔啉衍生物的制备方法
CN113527289A (zh) * 2015-09-23 2021-10-22 米纳瓦生物技术公司 筛选分化干细胞的试剂的方法
CN106967063A (zh) * 2017-03-21 2017-07-21 浙江大学 1‑三氟甲基‑1,2,3,4‑四氢‑β‑咔啉衍生物及其制备方法
CN106967063B (zh) * 2017-03-21 2019-01-11 浙江大学 1-三氟甲基-1,2,3,4-四氢-β-咔啉衍生物及其制备方法
CN110791389A (zh) * 2019-09-30 2020-02-14 义乌欧风汽车用品有限公司 一种环保型除胶剂及其制备方法和应用
CN110791389B (zh) * 2019-09-30 2021-06-01 义乌欧风汽车用品有限公司 一种除胶剂及其制备方法和应用

Also Published As

Publication number Publication date
US7855295B2 (en) 2010-12-21
WO2005070930A3 (en) 2006-01-19
US20050215580A1 (en) 2005-09-29
AU2005206570A1 (en) 2005-08-04
WO2005070930A2 (en) 2005-08-04
MXPA06008211A (es) 2006-08-31
BRPI0506977A (pt) 2007-07-03
JP2007518822A (ja) 2007-07-12
EP1706404A2 (en) 2006-10-04
CA2554150A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
CN1910183A (zh) 四氢咔啉化合物作为抗癌药
CN1798749A (zh) 作为抗癌剂的杂芳基－稠合的嘧啶基化合物
CN1809563A (zh) 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
CN1269813C (zh) 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1886384A (zh) 喹唑酮化合物作为抗癌药剂
CN1305850C (zh) 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
CN1196685C (zh) 嘧啶衍生物
CN100339376C (zh) 含氮芳环衍生物
CN1174981C (zh) 咪唑并[1,2-a]吡啶和吡唑并[2,3-a]吡啶衍生物
CN1420884A (zh) 2－取代的4－杂芳基－嘧啶及它们在治疗增殖性疾病中的用途
CN1889951A (zh) 取代的苯并唑及其用作raf激酶抑制剂的应用
CN101031560A (zh) 用作酪氨酸激酶抑制剂的环状二芳基脲
CN1960988A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1325390A (zh) 2－脲基噻唑衍生物及其制备方法和作为抗肿瘤剂的应用
CN1642915A (zh) 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物
CN1845734A (zh) 苯并咪唑衍生物及其作为蛋白激酶抑制剂的用途
CN1312807A (zh) 糖元合成酶激酶3的抑制剂
CN1071164A (zh) 含氮杂环化合物
CN1655779A (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
CN1703405A (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1656073A (zh) 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物
CN1582285A (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1852905A (zh) 具有n－取代的苯并咪唑基的c－kit抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

AD01 Patent right deemed abandoned

Effective date of abandoning: 20070207

C20 Patent right or utility model deemed to be abandoned or is abandoned